GHK-Cu Dosage: Injection Chart - Dosage Peptide

Search volume for “GHK-Cu dosage chart” is dominated by people who have already bought a 50 mg or 100 mg vial of blue powder and want to know two things: how much bacteriostatic water to add, and how many units to draw. The first question has a precise arithmetic answer. The second does not — and the honest reason why is the single most useful thing this page can tell you. GHK-Cu (copper tripeptide-1) is a cosmetic ingredient with a fifty-year topical research history and no approved injectable product, no published human injection trial, and no established parenteral dose in the peer-reviewed literature. This article gives you the reconstitution mathematics in full, shows exactly what published research and registered-product labelling actually used, and explains why the copper atom in the molecule makes “just inject it” a question with real pharmacological weight behind it.

What Is GHK-Cu, and What Do Regulators Actually Call It?

GHK is a tripeptide — glycyl-L-histidyl-L-lysine — isolated from human plasma in 1973 by Loren Pickart and Malcolm Thaler, who were investigating why serum from younger donors supported cultured liver cells better than serum from older donors.[1] The active fraction turned out to be a three-amino-acid sequence with high affinity for copper(II). GHK-Cu is the pre-formed 1:1 complex of that tripeptide with a copper ion.

The regulatory picture matters enormously here, and it is frequently blurred by vendor copy:

Cosmetic ingredient. Under the INCI naming system, GHK-Cu is copper tripeptide-1. This is its principal regulatory identity worldwide — an ingredient in leave-on and rinse-off cosmetic formulations. Cosmetic ingredients are not evaluated for efficacy the way drugs are.

Not an FDA-approved drug. There is no FDA-approved GHK-Cu drug product for any indication, in any route. Not topical, not injectable, not oral.

A pharmaceutical generic name exists. The GHK-copper complex carries the pharmaceutical generic name prezatide copper acetate, associated with the trade name Iamin, and is registered as such in the NCATS Inxight Drugs substance database.[2] The formulation that reached controlled human testing, and the only one for which a controlled human trial is retrievable, was a topical gel.[3] No injectable prezatide product has ever been approved in any jurisdiction.

Research chemical, when sold as a vial. A 50 mg or 100 mg lyophilised GHK-Cu vial sold “for research use only” is not a drug product, is not manufactured to injectable-drug standards by default, and carries no approved labelling to reference.

A note on precision, because this is the kind of claim that is easy to overstate. The defensible statement is narrow and it is enough: there is no FDA-approved GHK-Cu drug product for any indication, and no approved injectable GHK-Cu product in any jurisdiction. The regulatory status of the topical complex outside the United States is genuinely murky — the NCATS record for prezatide copper acetate carries a “Possibly Marketed Outside US” flag and lists cosmetic trade products, which is not the same thing as an approval as a medicine, but is also not a clean “never marketed anywhere.” Where the record is ambiguous, we say so rather than rounding it to whichever direction suits the argument.

So when someone searches for a GHK-Cu injection dosage chart, they are asking for the dosing table of a product that does not exist as an approved medicine anywhere in the world. That is not a technicality. It is the whole context. For a broader orientation to the compound before working through the numbers here, our overview of what GHK-Cu is, its proposed mechanisms, and its documented risks covers the compound’s biology in more depth.

The Chemical Identity, Precisely

Because every copper figure on this page derives from the molecular weight, the chemistry needs a real source rather than an assumption. PubChem lists copper tripeptide-1 (CAS 89030-95-5, UNII 6BJQ43T1I9) with the molecular formula C14H23CuN6O4+ and a molecular weight of approximately 402.9 g/mol.[15] Neutral and differently protonated depictions of the same complex are catalogued separately and sit between roughly 401 and 404 g/mol depending on how the coordinated ligand’s protonation state is drawn. That variation is chemically real and it is small: it moves the copper mass fraction by less than a tenth of a percentage point, which is far inside the uncertainty introduced by salt form and residual water in an actual vial. Throughout this article we use ~403 g/mol and a copper fraction of ~15.7%, and every derived figure should be read as an estimate with that tolerance, not as an analytical measurement.

Why the Blue Colour Is Diagnostic

Reconstituted GHK-Cu is a distinctly blue solution — not a faint tint, but a clear cobalt or teal blue depending on concentration. This is not a dye or a marketing flourish. It is the d-d electronic transition of the coordinated Cu(II) ion, the same physical phenomenon that makes copper sulphate solutions blue. Every other common research peptide reconstitutes to a colourless, water-clear solution. The blue is a visual reminder of the point the rest of this article keeps returning to: GHK-Cu is not just a peptide. It is a peptide plus a transition metal, and the metal has its own pharmacology and its own toxicology.

Research Context: Why “GHK-Cu Injection Dosage” Has No Evidence-Based Answer

It is worth stating this plainly and early, because it inverts the usual structure of a dosage page.

The GHK-Cu human evidence base is almost entirely topical. The mechanistic evidence base is almost entirely in vitro and animal. The injectable evidence base in humans is, as of this writing, effectively empty.

Consider what actually exists:

Human, topical, controlled: a multicentre randomised, vehicle-controlled trial of GHK-Cu gel (Iamin) in diabetic neuropathic ulcers, reported by Mulder and colleagues in Wound Repair and Regeneration in 1994.[3] This is one of the few genuinely controlled human GHK-Cu datasets, and it is a topical gel on an open wound.

Human, topical, cosmetic: a set of 12-week facial-cream studies in photoaged skin, the most frequently cited of which enrolled 71 women. These were presented as dermatology-meeting abstracts, were industry-associated, used surrogate cosmetic endpoints (skin density by ultrasound, wrinkle profilometry, investigator grading), and are summarised second-hand in review articles far more often than they are read in full.[4]

Human, topical, registered and ongoing: a trial of topical GHK-Cu gel (0.1% w/w) for acute skin wound healing versus vehicle gel in healthy adults was registered on ClinicalTrials.gov in 2026 (NCT07437586).[5] Note the route: topical. Again.

In vitro / animal: the large majority of the literature — fibroblast collagen synthesis, glycosaminoglycan and proteoglycan expression in rat wound models, gene-expression profiling via the Broad Institute Connectivity Map, rodent and rabbit wound models.[6][7]

Human, subcutaneous or intramuscular injection, controlled: none identified.

There is no published, peer-reviewed, controlled human trial establishing a subcutaneous or intramuscular GHK-Cu dose for any endpoint. There is no pharmacokinetic study in humans defining injected GHK-Cu’s half-life, distribution, copper handling, or accumulation. There is no dose-ranging study. There is no safety database.

Where the 1.7 mg Figure Actually Comes From

Every “1.7 mg daily, morning, 8 weeks on / 8 weeks off” protocol circulating on forums, vendor blogs, and peptide-clinic pages traces back to community convention, not to a citation. This is worth following carefully, because the failure mode is instructive.

When you chase those pages to their sources, one of three things happens. The citation resolves to a topical study — a cream on a face, a gel on an ulcer — which says nothing about an injected milligram figure. Or it resolves to in vitro work at nanomolar concentrations, which is six orders of magnitude away from a milligram dose and cannot generate one. Or there is no citation at all, and the number simply appears, already formatted, already confident. What does not happen, in our reading, is a citation resolving to a human study that administered 1.7 mg of GHK-Cu by injection and measured anything.

The number has been repeated enough times to acquire the texture of a fact. Repetition is not evidence, and a figure that is universally quoted and never sourced is a rumour with good distribution. We name it here only to take it apart — a page that quietly omitted it would leave the reader to find it somewhere less careful.

This site’s position is straightforward: we will show you the reconstitution arithmetic, because that arithmetic is real, checkable, and useful. We will not manufacture an injection dose to fill a gap that the literature has left empty.

What Is Actually Inside a 50 mg or 100 mg GHK-Cu Vial?

Before any chart makes sense, the contents of the vial need unpacking — because the vial sizes on the research market are, pharmacologically speaking, remarkably large.

The Copper Fraction

Using the molecular weight established above (~403 g/mol) and copper’s atomic weight of 63.55:[15]

63.55 ÷ 403 ≈ 0.157, or roughly 15.7% copper by mass.

Apply that to the two vial sizes on the market:

50 mg

~7.9 mg Cu

100 mg

~15.7 mg Cu

Caveat on this arithmetic: many commercial “GHK-Cu” powders are supplied as an acetate salt (copper tripeptide-1 ·xHOAc), which lowers the copper fraction below 15.7% by an amount that depends on the acetate stoichiometry and residual water. Purity and actual copper loading are not verifiable without a certificate of analysis and, ideally, independent elemental analysis. Treat 15.7% as an upper-bound estimate for pure complex, and understand that the real figure for any given vial is unknown to the buyer.

Putting That Copper in Context

This is where the vial-size reality becomes striking. Compare the copper in a single 100 mg vial to established copper intake reference points:

RDA, adults

900 µg/day (0.9 mg)

Oral

IOM / NIH ODS[8]

Typical US dietary intake

~1.0–1.6 mg/day

NIH ODS[8]

Tolerable Upper Intake Level (UL), adults

10 mg/day

IOM DRI, based on liver damage as the critical adverse effect[9]

ASPEN parenteral nutrition copper dose, adults

0.3–0.5 mg/day

Intravenous

Parenteral trace-element review[10]

One 100 mg GHK-Cu vial

—

Calculated from MW[15]

One 50 mg GHK-Cu vial

Read that table again. A single 100 mg vial contains more elemental copper than the oral Tolerable Upper Intake Level for an entire day — and roughly 30 to 50 times the daily copper dose that clinicians deliver intravenously to patients on total parenteral nutrition, where copper is dosed conservatively precisely because the parenteral route bypasses gut regulation. Nobody is proposing injecting an entire vial at once, and the per-dose fractions are far smaller. But the vial itself is a reservoir of copper on a scale that dietary and clinical frameworks treat with care.

The Concentration Gap

There is a second, quieter mismatch. The in vitro literature on which GHK-Cu’s reputation is built works at nanomolar concentrations. The original fibroblast collagen-synthesis work reported stimulation beginning between 10-12 and 10-11 M and peaking at 10-9 M — that is, one nanomolar.[14] Review literature reports that endogenous plasma GHK falls from roughly 200 ng/mL around age 20 to under 80 ng/mL by age 60.[4]

Convert those units for comparison. 200 ng/mL of a ~403 g/mol molecule is roughly 0.5 µmol/L. The physiological system that GHK-Cu research describes operates at sub-microgram-per-millilitre concentrations. A 100 mg vial reconstituted in 3 mL sits at 33.3 milligrams per millilitre — approximately 160,000-fold more concentrated than young-adult plasma GHK. Diluting that into an adult’s ~3 litres of plasma changes the arithmetic considerably, but the point stands: the vial format was designed around commercial convenience, not around any dose that the mechanistic literature identified as biologically relevant. Nothing in the in vitro data implies that “more” is better; the original dose-response curve was reported to peak at 1 nM rather than to rise monotonically, which is the signature of a biphasic effect rather than a linear one.[14]

GHK-Cu Dosage Chart: Reconstitution Arithmetic, Reference Tables, and Storage

This part is genuinely simple, and it is the part we can give you with confidence, because it is arithmetic rather than pharmacology. It is the same arithmetic for every lyophilised peptide, and it is worked through in more general form in our peptide reconstitution guide.

The Two Formulas

Concentration:

If you add Y mL of bacteriostatic water to a vial containing X mg of GHK-Cu:

Concentration (mg/mL) = X ÷ Y

Amount per insulin-syringe unit:

A U-100 insulin syringe holds 100 units per 1 mL. Therefore 1 unit = 0.01 mL. So:

mg per unit = (X ÷ Y) ÷ 100

mcg per unit = (X ÷ Y) × 10

That second form is the one worth memorising: divide milligrams by millilitres, multiply by ten, and you have micrograms per unit.

Worked Example, Step by Step

Take a 50 mg vial and 2 mL of bacteriostatic water.

Concentration = 50 mg ÷ 2 mL = 25 mg/mL

Per unit (mg) = 25 ÷ 100 = 0.25 mg per unit

Per unit (mcg) = 0.25 mg × 1000 = 250 mcg per unit

Cross-check with the shortcut: (50 ÷ 2) × 10 = 25 × 10 = 250 mcg per unit ✓

Now a 100 mg vial and 5 mL:

Concentration = 100 mg ÷ 5 mL = 20 mg/mL

Per unit = (100 ÷ 5) × 10 = 20 × 10 = 200 mcg per unit

If you want to check any figure in the tables below without doing it by hand, our reconstitution and dosage calculator runs the same arithmetic and will reproduce these numbers exactly.

A Physical Constraint People Forget

The bacteriostatic water has to physically fit in the vial. Many 50 mg and 100 mg research vials are small-format — 2 mL or 3 mL nominal capacity — and cannot accept 5 mL or 10 mL of diluent regardless of what a chart says. Before choosing a dilution, look at the vial. If it will not hold the volume, that row of the table is arithmetic that describes a solution you cannot actually make. This is covered in more detail in our guide to how much bacteriostatic water to use for reconstitution.

The tables below are concentration references, not dosing recommendations. They tell you what a given dilution yields per syringe unit. They do not tell you how many units anyone should draw, because — as established above — no published human injection standard exists to tell you that.

GHK-Cu 50 mg Vial: Reconstitution Chart

1 mL

50 mg/mL

500 mcg

5 mg

10 mg

(50÷1)×10 = 500

2 mL

25 mg/mL

250 mcg

2.5 mg

(50÷2)×10 = 250

2.5 mL

20 mg/mL

200 mcg

2 mg

4 mg

(50÷2.5)×10 = 200

3 mL

16.67 mg/mL

166.7 mcg

1.67 mg

3.33 mg

(50÷3)×10 = 166.7

5 mL

10 mg/mL

100 mcg

1 mg

(50÷5)×10 = 100

10 mL

5 mg/mL

50 mcg

0.5 mg

(50÷10)×10 = 50

GHK-Cu 100 mg Vial: Reconstitution Chart

100 mg/mL

1000 mcg (1 mg)

20 mg

(100÷1)×10 = 1000

(100÷2)×10 = 500

33.33 mg/mL

333.3 mcg

6.67 mg

(100÷3)×10 = 333.3

4 mL

(100÷4)×10 = 250

(100÷5)×10 = 200

(100÷10)×10 = 100

The Same Tables, Expressed as Copper

Because copper is the part of this molecule with a real toxicological literature, it is worth seeing the charts a second way. Using the ~15.7% figure derived earlier, and remembering that the parenteral nutrition reference range for adults is 0.3–0.5 mg (300–500 µg) of copper per day:[10]

~79 µg

~9% of the adult oral RDA

~157 µg

~17% of the adult oral RDA

1.7 mg

~267 µg

Just below the lower end of the daily intravenous copper dose in parenteral nutrition (0.3–0.5 mg)[10]

3 mg

~472 µg

Approaching the upper end of the daily parenteral nutrition copper dose (0.3–0.5 mg) — roughly 0.94× that upper figure

~785 µg

~1.6× the upper end of the daily parenteral copper dose

~1.57 mg

~3–5× the daily parenteral copper dose; ~1.7× the oral RDA

The widely repeated community figure of 1.7 mg/day delivers, by this estimate, roughly 267 µg of copper directly into tissue — the same order of magnitude as what a clinical team would deliver intravenously over a full day to a patient receiving all their nutrition parenterally, and which they would reduce, with monitoring of serum concentrations, in the presence of cholestasis because of accumulation risk.[10] That parallel is not proof of harm. It is a demonstration that the community number, which is often presented as trivially small, is not trivially small in the one frame of reference that has actual clinical dosing precedent behind it.

Storage and Stability: General Practice for Lyophilised Peptides

Before reconstitution: lyophilised powder is the stable form. Standard laboratory practice is refrigeration at 2–8°C for medium-term storage, or freezing at −20°C or below for long-term, with the vial protected from light and moisture. Allow the vial to reach room temperature before opening to avoid condensation drawing water into the powder.

After reconstitution: the peptide is in solution and the clock starts. Refrigerate at 2–8°C. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what makes repeated withdrawal from a vial possible at all; sterile water without preservative does not.

Avoid: repeated freeze-thaw cycles of the reconstituted solution, vigorous shaking (direct the diluent stream down the vial wall and swirl gently rather than agitating), and prolonged light exposure.

Our guide to storing peptides before and after reconstitution covers the general principles in full.

The Copper-Specific Stability Consideration

GHK-Cu differs from an ordinary peptide in one respect that matters for stability assessment: the blue colour is a direct readout of the copper coordination state. A GHK-Cu solution that has lost its blue, changed hue substantially, developed a green tinge, or shows visible precipitate is telling you something about the complex that a colourless peptide solution could not. Copper complexes are also pH-sensitive in their coordination chemistry, and Cu(II) is redox-active in ways that a metal-free peptide is not.

Being precise: published stability data for reconstituted GHK-Cu in bacteriostatic water — how long the complex remains intact, at what temperature, at what pH — is not something we have been able to source in the peer-reviewed literature. Vendor stability claims are not independently verified. What can be said honestly is that visual change is meaningful information and that the absence of published stability data for this specific handling scenario is itself a limitation.

Mechanisms Studied

GHK-Cu’s mechanistic literature is genuinely substantial — it is simply, almost without exception, preclinical. Here is what has actually been investigated, and at what tier.

Copper Transport

The foundational hypothesis, developed across Pickart’s work, is that GHK acts as a copper-carrier: it binds Cu(II) with high affinity in a form that can exchange copper with cellular transport systems, effectively delivering copper to enzymes that require it. The 1980 Nature report showed that the tripeptide forms complexes with copper(II) and enhances uptake of the metal into cultured hepatoma cells, and noted a structural homology between GHK and the copper-transport sites on albumin and alpha-fetoprotein.[11] Copper is a cofactor for lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase (antioxidant defence), cytochrome c oxidase (cellular respiration), and tyrosinase, among others. The proposal is that GHK’s biological effects are substantially copper-delivery effects. Tier: mechanistic, in vitro and biochemical.

Extracellular Matrix Synthesis

In fibroblast culture, GHK-Cu has been reported to stimulate collagen synthesis, with the effect beginning in the picomolar range and maximising at 1 nM, independent of any change in cell number.[14] In dermal fibroblast culture and in rat wound-chamber models, GHK-Cu has been reported to modulate glycosaminoglycan and small-proteoglycan synthesis — increasing chondroitin sulphate and dermatan sulphate accumulation, raising decorin mRNA and lowering biglycan mRNA — i.e. to shift matrix composition rather than simply to increase it.[7] Reviews additionally describe effects on elastin and on the balance of matrix metalloproteinases against their tissue inhibitors, though these are secondary summaries rather than primary human-tissue datasets.[4] Tier: in vitro cell culture plus animal in vivo.

Gene-Expression Modulation

The most-cited modern work applied the Broad Institute’s Connectivity Map to GHK, reporting that the peptide modulates expression of a large number of human genes — with reviews describing shifts in several thousand genes at 1 µM in cultured cells, including genes involved in DNA repair, antioxidant response, and inflammatory signalling.[6] This is where phrases like “resets gene expression back to health” originate. It is important to be precise about what this is: a computational analysis of transcriptional signatures in cell lines. Transcriptional change in a cultured cell line is a hypothesis-generating observation. It is not a clinical outcome, and the leap from “modulates gene expression in vitro” to “produces a therapeutic effect in a person” is exactly the leap that most preclinical findings fail to make. Tier: in vitro transcriptomics / computational.

Wound Healing Models

Animal wound models — rodent, rabbit, and porcine — have reported accelerated closure, improved granulation tissue, and better collagen organisation with GHK-Cu.[4] The single strongest human translation of this is the Mulder diabetic neuropathic ulcer trial, which reported significantly greater plantar-ulcer closure with GHK-Cu gel than with vehicle.[3] That trial is real, controlled, and topical — on damaged skin, where the epidermal barrier is already breached. Its findings say nothing about injecting the compound into intact tissue. Tier: animal models plus one controlled human topical trial.

Hair Follicle Effects

Copper-peptide hair claims are among the most widely repeated things said about this compound, and they are among the least supported at the human level. There is no controlled human trial demonstrating that GHK-Cu — topical or injected — regrows hair in androgenetic alopecia or any other hair-loss condition, and the compound should not be described as a hair-loss treatment. Where follicle claims appear in secondary sources, the underlying material is preclinical and topical; we are not aware of a retrievable primary human dataset, and rather than cite an animal finding we cannot verify to the record, we state only the negative claim, which needs no positive source. Tier: no controlled human evidence.

Current Evidence Level

Here is the tier map in a single view. This is the table to read if you read nothing else on the page.

Improves cosmetic appearance of photoaged skin

Topical

Small human studies, largely industry-associated, surrogate endpoints, several published only as meeting abstracts

No FDA-approved drug product; cosmetic ingredient status only

Accelerates closure of diabetic neuropathic ulcers

Topical gel

One multicentre randomised, vehicle-controlled human trial (1994)[3]

No FDA-approved drug product; no approved injectable product in any jurisdiction. Regulatory status of the topical complex outside the US is unclear in the NCATS record[2]

Accelerates acute wound re-epithelialisation

Registered trial in progress (NCT07437586)[5] — no results

No

Stimulates collagen synthesis in fibroblasts

Cell culture

In vitro, nanomolar dose-response[14]

N/A

Modulates glycosaminoglycan and small-proteoglycan expression

Cell culture + rat wound chamber

In vitro plus animal in vivo[7]

Broad gene-expression modulation, “anti-aging” signature

In vitro transcriptomics / Connectivity Map analysis[6]

Systemic effects (lung, nerve, cognition, cancer)

Various, preclinical

In vitro and animal only; discussed as hypotheses in review articles[6]

Any effect from subcutaneous or IM injection in humans

Injectable

None — no controlled human trial identified

No approved injectable product exists in any jurisdiction

Injected GHK-Cu pharmacokinetics in humans

None identified

A Note on the Review Literature

An unusual feature of GHK-Cu’s evidence base deserves flagging, because it shapes how the compound is perceived. A large share of the accessible, highly-cited GHK-Cu literature consists of review articles authored by the same small group — principally Loren Pickart, the compound’s discoverer, with co-authors, published across several journals between roughly 2012 and 2018.[4][6] These are legitimate, peer-reviewed publications and are the best available synthesis of the field. They are also reviews, not new trials, and their author had a long commercial association with the compound’s development. When a secondary source cites “dozens of studies,” a meaningful fraction of those citations resolve to this review cluster or to the primary in vitro work it summarises — not to independent replication in humans. Citation count in this field is not a proxy for evidentiary weight.

What Amounts, Routes and Frequencies Does the Literature Actually Report?

Here is the honest version of the “protocol table” that dosage pages normally fill with confident numbers. Each row states what was actually used, in what species, by what route, with the citation — and each row that has no evidence says so.

Diabetic neuropathic ulcers (Iamin gel / prezatide copper acetate)

Topical gel formulation; concentration per product formulation, not a systemic dose

Topical, to the ulcer bed

Applied per protocol over the trial period

Multicentre randomised, vehicle-controlled human trial, 1994[3]

Photoaged facial skin, cosmetic cream

GHK-Cu as a cosmetic-concentration ingredient in cream base

Topical, facial and periocular

Daily, 12 weeks

Small human studies, largely abstract-level and industry-associated[4]

Acute standardised skin wounds

Topical GHK-Cu gel 0.1% w/w vs vehicle gel

Per registered protocol

Registered trial, recruiting, no results posted[5]

Rat experimental wound chambers

2 mg per injection

Repeated injection into the implanted wound chamber

Repeated over a 22-day experimental period

Animal in vivo — the only quantified injected GHK-Cu amount we can source[7]

Fibroblast collagen synthesis

Threshold 10-12–10-11 M; maximal at 10-9 M (1 nM)

Cell culture medium

Per assay

In vitro[14]

Gene-expression profiling

~1 µM

In vitro transcriptomics[6]

Endogenous human plasma GHK

~200 ng/mL at age 20, falling to <80 ng/mL by age 60

Endogenous

Continuous

Reported in review literature[4]

Subcutaneous injection in humans

No established amount

Subcutaneous

No established frequency or duration

No human standard exists. Circulating figures (e.g. “1.7 mg daily, 8 weeks on / 8 weeks off”) are community convention with no primary citation.

Intramuscular injection in humans

Intramuscular

No human standard exists.

Notice what happens when the table is filled honestly. Every row with a number attached to it is topical, in vitro, or rodent. Every row describing human injection is empty. That pattern is the finding.

The rat row deserves a moment, because it is the closest thing in the literature to an injected GHK-Cu amount, and it demonstrates precisely why proximity is not equivalence. Siméon and colleagues delivered 2 mg per injection — but into a surgically implanted wound chamber in a rat, a local compartment in an animal roughly one two-hundredth of a human’s mass, as an experimental method for concentrating the compound at a healing site.[7] It is not a systemic dose, it is not a human dose, and it was never intended as either. Anyone tempted to notice that 2 mg is reassuringly close to the community’s 1.7 mg figure should notice instead that a rodent wound-chamber method is not a dose-finding study, and that the resemblance is a coincidence of scale rather than a validation.

Our protocol reference pages for the two common vial formats — the GHK-Cu 50 mg vial dosage protocol and the GHK-Cu 100 mg vial dosage protocol — set out the same reconstitution mathematics against each vial’s specific handling considerations, and carry the same evidentiary caveats.

Why Copper Is the Central Safety Question

Most peptide safety discussions are about the peptide. For GHK-Cu, the more consequential half of the molecule is the metal, and this deserves more than a footnote.

Copper Is Homeostatically Regulated — and Injection Bypasses the Regulator

The human body controls copper tightly. Dietary copper is absorbed in the small intestine at a fractional absorption rate that adjusts inversely to intake: when intake is low, a larger fraction is absorbed; when intake is high, absorption falls and biliary excretion rises.[8] The liver is the central regulator, packaging copper into ceruloplasmin for distribution and excreting the excess into bile. Bile is the primary elimination route for copper; renal excretion is minor.

This system is why the oral Tolerable Upper Intake Level sits at 10 mg/day while typical dietary intake is 1–1.6 mg/day — there is substantial regulated headroom, because the gut and liver are actively managing the load.[9]

Parenteral administration bypasses the gut entirely. Copper injected subcutaneously or intravenously does not pass through the regulated absorptive step. It arrives in the systemic circulation regardless of the body’s copper status. This is not a speculative concern — it is precisely why parenteral nutrition copper dosing is an order of magnitude lower than oral intake, at 0.3–0.5 mg/day, and why the dose is reduced, with monitoring of serum concentrations, in cholestasis where biliary excretion is impaired.[10] It is worth being exact about what that source says, because the naive reading goes too far in the other direction: the recommendation is to adjust the parenteral copper dose according to serum concentrations and the clinical picture, explicitly not to stop it, since discontinuing copper in cholestatic patients risks producing copper deficiency instead. The clinical posture is titration under measurement, in both directions. That is the opposite of a fixed community protocol run without any measurement at all.

Clinical nutrition teams treat injected copper as a fundamentally different exposure from eaten copper, and they dose it conservatively for a mechanistic reason that applies identically to an injected copper-peptide complex.

What Copper Excess Does

The IOM set the copper UL on the basis of liver damage as the critical adverse effect.[9] Copper’s toxicity mechanism is well characterised: free or loosely bound Cu(II)/Cu(I) participates in Fenton-type redox chemistry, generating hydroxyl radicals that damage lipids, proteins, and DNA. The clinical extreme of chronic copper overload is Wilson disease, in which impaired biliary copper excretion produces hepatic and neurological injury — a natural experiment demonstrating what happens when the copper regulatory system fails.[8] Acute copper toxicity produces gastrointestinal effects; chronic excess targets the liver. The ATSDR toxicological profile compiles the human and animal toxicity database.[12]

To be scrupulously fair: GHK-Cu is a chelated copper complex, and chelation is precisely the argument its proponents make — that bound copper is not free copper, that the tripeptide delivers copper into physiological handling pathways rather than dumping ionic copper into tissue. That argument is mechanistically coherent and it is the basis of the entire GHK-Cu hypothesis.[11] But it is an argument, not a dataset. Nobody has published human pharmacokinetics showing what happens to the copper after a subcutaneous GHK-Cu injection: how much dissociates locally, how much reaches the liver, whether repeated administration accumulates, what happens to ceruloplasmin and serum copper over weeks. Those studies do not exist. “It’s chelated, so it’s fine” is a hypothesis that has never been tested in a person by this route.

It is worth noting the shape of the missing study, because it is not exotic. Serum copper, ceruloplasmin, and liver enzymes are ordinary, inexpensive assays. A small cohort, repeated dosing, serial measurement over eight weeks would answer the central question of whether injected GHK-Cu accumulates copper. That such a study has not been done — despite fifty years of interest in the molecule and a large commercial market in vials — is itself informative about how much of the injectable use is driven by evidence and how much by momentum.

Copper–Zinc Antagonism

Copper and zinc compete for absorption and share regulatory pathways. High copper intake can affect zinc status, and — more commonly documented — high zinc intake induces intestinal metallothionein and causes copper deficiency. Anyone considering the copper load of a GHK-Cu vial in the context of other supplementation should understand that these two metals are coupled, and that the coupling is a documented clinical phenomenon rather than a theoretical one.[8] The interaction is also route-dependent in a way that undercuts easy reasoning: the zinc–copper antagonism operates largely at the intestinal absorptive step, so an injected copper load does not interact with oral zinc the way an oral copper load would. This is one more instance of the same theme — intuitions built on dietary mineral behaviour do not transfer cleanly to the parenteral route.

Local Injection-Site Effects

Reports of pain, burning, marked erythema, swelling and prolonged stinging at GHK-Cu injection sites are widespread in user communities and vendor literature. These reports are anecdotal — there is no published case series or trial safety database for injected GHK-Cu, so their frequency and severity are genuinely unknown.

The mechanistic plausibility, however, is not anecdotal. Subcutaneous tissue is densely populated with mast cells, and cationic peptides are established activators of the MRGPRX2 receptor on human skin mast cells, triggering degranulation and histamine release through a signalling cascade that has been characterised in some detail in primary human skin mast cells.[13] GHK carries a lysine residue and is cationic. Separately, copper ions have direct irritant and pro-oxidant potential in tissue. Both mechanisms are real; whether either explains the anecdotal reports has not been formally studied. The correct summary is: a plausible mechanism exists, the reports are consistent with it, and nobody has done the work to confirm it.

Injectable vs Topical: What the Route Actually Changes

The route difference here is not a detail — it is the difference between the evidence base that exists and the one that doesn’t.

The Case for Topical

Every controlled human GHK-Cu dataset is topical. The 1994 ulcer trial, the photoaging creams, the 2026 registered wound-healing study — all topical.[3][5] Topical application also keeps the copper load overwhelmingly local: intact stratum corneum is a substantial barrier to a ~403 Da charged metal complex, which limits systemic copper exposure — the same barrier property that limits topical efficacy is what limits topical copper risk. The trade-off is explicit and it favours safety.

The Case Against Injection

Injection is often framed as “topical but better” — same molecule, better delivery, systemic reach. The framing conceals three separate leaps:

An efficacy leap. Nothing demonstrates that systemic GHK-Cu produces the effects that topical GHK-Cu was studied for. Skin effects from a cream on skin do not predict skin effects from a peptide in the bloodstream, and the systemic claims in the review literature are preclinical hypotheses.[6]

A safety leap. Injection removes the barrier that was containing the copper. The exposure profile is categorically different, and it is different in the direction that clinical practice treats with the most caution.[10]

A product-quality leap. Research-use-only vials are not manufactured as injectable drug products. Sterility, endotoxin content, elemental impurities, and actual copper stoichiometry are not verified for this use. And the formulation that carried GHK-Cu into controlled human testing under a pharmaceutical generic name was a topical gel, not an injection — the one time the compound was developed with regulatory intent, the route chosen was the skin.[3][2]

We examine this route comparison in dedicated detail in our analysis of injectable versus topical GHK-Cu in the skin research literature, and the specific question of systemic exposure in what the research says about subcutaneous and systemic injectable GHK-Cu.

Limitations and What the Evidence Does Not Establish

This section is the one most dosage pages omit. It is the most important one here.

Limitations of the Existing Evidence

Route mismatch. The evidence is topical; the search intent is injectable. These are not interchangeable.

Concentration mismatch. The mechanistic work is nanomolar-to-micromolar in cell culture. The vials are milligram-scale. The literature offers no bridge between them.

Species mismatch. The strongest in vivo matrix data come from rat wound chambers. Rodent wound biology differs materially from human wound biology, and a local implanted compartment is not a subcutaneous injection.

Endpoint quality. The photoaging studies used surrogate cosmetic endpoints — skin density on ultrasound, wrinkle profilometry, investigator visual grading. These are legitimate cosmetic-science endpoints. They are not clinical outcomes.

Publication format. Several of the most-cited human GHK-Cu results exist as dermatology-conference abstracts, not as full peer-reviewed papers with complete methods available for scrutiny.

Independence. A substantial share of the literature originates from the discoverer’s group or from parties with commercial interests in the compound. This does not make the findings wrong. It does mean independent replication is thinner than the citation count suggests.

Small n. Human studies are in the tens of participants. The 1994 ulcer trial is the methodologically strongest human dataset and it is over thirty years old, on a product whose development was subsequently abandoned.

No pharmacokinetics. No human PK data exist for injected GHK-Cu: no half-life, no distribution, no metabolic fate of the copper, no accumulation data.

Product uncertainty. Purity, stoichiometry, and actual copper content of research-market vials are unverified by the buyer.

What the Evidence Does Not Establish

Stated as plainly as we can:

It does not establish a safe or effective injectable dose of GHK-Cu in humans, for any endpoint, at any frequency, for any duration.

It does not establish that GHK-Cu reverses aging. Gene-expression shifts in cultured cells are not aging reversal.

It does not establish that GHK-Cu regrows hair in humans. There is no controlled human trial of hair regrowth by any route.

It does not establish that GHK-Cu heals wounds as a general human fact. One 1994 topical trial in one specific ulcer population is a data point, not a general claim, and the product it studied was never approved.

It does not establish that injected GHK-Cu is systemically safe, that the chelated copper is handled benignly, or that repeated administration does not accumulate copper.

It does not establish that “cycling” — 8 weeks on, 8 weeks off, or any other schedule — mitigates any risk. Cycling schedules for GHK-Cu are a community heuristic with no supporting data. They may be prudent; they are not evidenced.

It does not establish that GHK-Cu treats, cures, or prevents any disease. No regulator anywhere has approved it as a drug for anything.

What the Evidence Does Establish

In fairness, this is not a nothing-burger. What holds up:

GHK is a real endogenous human plasma tripeptide, discovered in 1973, and its plasma concentration is reported to decline with age.[1][4]

It binds Cu(II) with high affinity, enhances copper uptake into cultured cells, and has a coherent, biochemically grounded copper-transport rationale.[11]

It has reported effects on matrix synthesis in fibroblast culture at nanomolar concentrations, with a characterised dose-response curve.[14] Whether those effects have been independently replicated across groups to the standard the word “reproducible” implies is a separate question, and one this article is deliberately not asserting.

A topical formulation outperformed vehicle in a controlled human ulcer trial.[3]

The topical wound-healing question is currently under formal investigation.[5]

That is a genuinely interesting preclinical and topical compound. It is not an injectable protocol. The gap between those two descriptions is where this entire search category lives.

Frequently Asked Questions

How much bacteriostatic water should I add to a 50 mg GHK-Cu vial?

That depends on the concentration you want and on the vial’s physical capacity. Common choices are 2 mL (giving 25 mg/mL, or 250 mcg per insulin-syringe unit) or 5 mL (giving 10 mg/mL, or 100 mcg per unit). The arithmetic is: concentration = mg ÷ mL, and mcg per unit = (mg ÷ mL) × 10. Check the vial’s capacity before choosing — many small-format vials cannot physically accept 5 or 10 mL. Reconstitution volume is a dilution decision, not a dosing decision.

What is the correct GHK-Cu injection dosage?

There isn’t an established one. No controlled human trial has ever defined a subcutaneous or intramuscular GHK-Cu dose for any endpoint, and no injectable GHK-Cu product is approved anywhere. The figures circulating online — most commonly 1.7 mg daily — come from community convention rather than from any primary source. Any page presenting an injection dose as evidence-based is presenting something the peer-reviewed literature does not contain. That absence is a finding, not an oversight on our part.

How many units of GHK-Cu is 1 mg?

It depends entirely on your dilution. At 25 mg/mL (50 mg in 2 mL), 1 mg = 4 units. At 20 mg/mL (100 mg in 5 mL), 1 mg = 5 units. At 10 mg/mL (50 mg in 5 mL or 100 mg in 10 mL), 1 mg = 10 units. At 33.33 mg/mL (100 mg in 3 mL), 1 mg = 3 units. The general formula: units = desired mg ÷ (mg per mL) × 100. Our insulin syringe units guide walks through unit conversion in detail.

How much copper is in a 100 mg GHK-Cu vial?

Approximately 15.7 mg of elemental copper, calculated from copper’s atomic weight (63.55) divided by GHK-Cu’s molecular weight (~403), giving a ~15.7% copper mass fraction. For a 50 mg vial, roughly 7.9 mg. For comparison, the adult oral Tolerable Upper Intake Level for copper is 10 mg/day, and the intravenous copper dose in parenteral nutrition is 0.3–0.5 mg/day. Acetate-salt formulations contain somewhat less copper than the pure complex.

Why is my reconstituted GHK-Cu blue?

The blue colour comes from the coordinated copper(II) ion — it is the d-d electronic transition of Cu(II) in the peptide complex, the same physics that makes copper sulphate solutions blue. It is expected and it is not a contaminant. It is also a useful signal: a solution that loses its blue, turns green, or develops visible precipitate is indicating a change in the copper coordination state or the integrity of the complex.

Is GHK-Cu FDA approved?

No. GHK-Cu is not an FDA-approved drug for any indication by any route. Its principal regulatory identity is as a cosmetic ingredient under the INCI name copper tripeptide-1. It carries a pharmaceutical generic name, prezatide copper acetate (Iamin), and the formulation that reached controlled human testing under that name was a topical gel — but no approval followed. There is no approved injectable GHK-Cu product anywhere in the world.

Is injectable GHK-Cu safer or more effective than topical?

The evidence does not support that, and it points the other way on safety. Every controlled human GHK-Cu study is topical. Injection removes the skin barrier that limits systemic copper exposure, delivering a copper complex past the gut’s regulated absorption step — the same reason clinical teams dose intravenous copper an order of magnitude below oral intake. There are no human injection efficacy data, no injection pharmacokinetics, and no injection safety database to weigh against topical.

Does GHK-Cu regrow hair or reverse aging?

Neither is established in humans. There is no controlled human trial demonstrating hair regrowth in androgenetic alopecia with GHK-Cu by any route; the follicle claims circulating online rest on preclinical, topical material. The “reverses aging” language derives from in vitro gene-expression profiling in cell lines — a hypothesis-generating computational finding, not a clinical outcome. No aging-reversal endpoint has been demonstrated with GHK-Cu in a controlled human study.

Why do 50 mg and 100 mg vials exist if the research used nanomolar concentrations?

Vial sizing on the research-chemical market reflects commercial packaging convention, not a dose derived from the literature. The in vitro work that established GHK-Cu’s mechanistic reputation reported a collagen-synthesis effect peaking at 1 nM in cell culture, and endogenous plasma GHK sits around 200 ng/mL in young adults. A 100 mg vial is orders of magnitude removed from those figures. The vial size should not be read as an implicit dosing signal.

References

Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85–87. PMID 4349963. https://pubmed.ncbi.nlm.nih.gov/4349963/

NCATS Inxight Drugs. Prezatide copper acetate (bis(tripeptide-1) copper acetate) — substance record (UNII A3LEI4P1NB). https://drugs.ncats.io/drug/A3LEI4P1NB

Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair Regen. 1994;2(4):259–269. PMID 17147644. https://pubmed.ncbi.nlm.nih.gov/17147644/

Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/

ClinicalTrials.gov. Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal). NCT07437586. https://clinicaltrials.gov/study/NCT07437586

Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide–copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962–968. PMID 11121126. https://pubmed.ncbi.nlm.nih.gov/11121126/

National Institutes of Health, Office of Dietary Supplements. Copper — Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/

Institute of Medicine (US) Panel on Micronutrients. Copper. In: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academies Press; 2001. https://www.ncbi.nlm.nih.gov/books/NBK222312/

Perks P, Huynh E, Kaluza K, Boullata JI. Advances in trace element supplementation for parenteral nutrition. Nutrients. 2022;14(9):1770. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105959/

Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715–717. PMID 7453802. https://pubmed.ncbi.nlm.nih.gov/7453802/

Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Copper. https://www.atsdr.cdc.gov/ToxProfiles/tp132.pdf

Wang Z, Franke K, Bal G, Li Z, Zuberbier T, Babina M. MRGPRX2-mediated degranulation of human skin mast cells requires the operation of Gαi, Gαq, Ca²⁺ channels, ERK1/2 and PI3K — interconnection between early and late signaling. Cells. 2022;11(6):953. PMID 35326404. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946553/

Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide–copper complex glycyl-L-histidyl-L-lysine-Cu²⁺. FEBS Lett. 1988;238(2):343–346. PMID 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/

PubChem, National Library of Medicine. Copper tripeptide-1 (GHK-Cu), CID 71587328 — CAS 89030-95-5, molecular formula and molecular weight. https://pubchem.ncbi.nlm.nih.gov/compound/71587328

Research-use-only disclaimer. Dosage Peptide is an independent reference library. We do not sell peptides and have no commercial interest in any compound described here. This article is a description of what the published scientific literature, registered trials, and regulatory documentation report about GHK-Cu — it is not medical advice, not a treatment protocol, and not a recommendation that any person administer this or any compound to themselves or to anyone else. GHK-Cu is not an FDA-approved drug for any indication, and no approved injectable GHK-Cu product exists in any jurisdiction. The reconstitution arithmetic presented here describes laboratory concentration calculations; it does not constitute a dosing recommendation, and the absence of an established human injection dose in this article reflects the actual state of the peer-reviewed literature. Copper-containing compounds carry documented toxicological considerations, and the parenteral route bypasses the physiological mechanisms that regulate copper absorption. Nothing here should be interpreted as suggesting that GHK-Cu treats, cures, prevents, or mitigates any disease or condition. Consult a qualified, licensed healthcare professional regarding any health question.